The molecular pathogenesis of endometrial cancer is not yet completely understood, preventing the development of successful therapies. Here, we determine the effect of CYPB on the growth of endometrial cancer.
Introduction 3
Endometrial cancer represents a group of epithelial malignant tumors occurring in the endometrium and is one of the three most common malignant tumors of the female genital tract. Seventy-five percent of the patients are diagnosed in an early phase, and the 5-year survival rate was 65-92% [1, 2] . Molecular pathogenesis of endometrial cancer involves abnormalities in many genes and signaling pathways. For example, mutations in P53, increased microsatellite instability, mutations in PTEN, and abnormalities in the Notch signaling pathway all lead to uncontrolled cell proliferation and apoptosis, which in turn lead to the occurrence and development of endometrial cancer [3] [4] [5] [6] . At present, the molecular pathogenesis of endometrial cancer is not entirely understood, and further research is warranted in order to develop successful therapies.
Cyclophilins are highly conserved proteins that are ubiquitously expressed intracellularly.
They were first recognized as host cell receptors for the potent immunosuppressive drug cyclosporin A [7, 8] . They act as molecular chaperones that fold, translocate, and process newly synthesized proteins. Cyclophilin B (CYPB) is a 21 kDa peptidyl-prolyl cis-trans isomerase [9] that is expressed in the endoplasmic reticulum (ER) lumen [10] and nucleus [11] . It has been implicated in hepatitis virus replication [12] , immunosuppression [13] , chemotaxis [14] , and prolactin signaling [15] . Moreover, its increased expression may significantly contribute to the pathogenesis of human breast cancer [16] , myeloma [17] , hepatic carcinoma [18] , gastric cancer [19] , head and neck squamous cell carcinoma [20] , and glioblastoma [21] . Finally, it has also been used as a serum biomarker for early detection of pancreatic cancer [22] . However, to date, no study has investigated the role of CYPB in endometrial cancer.
Hence, to determine the effect of CYPB on the growth of endometrial cancer, we aimed to assess its expression in endometrial tissues and CYPB-silenced HEC-1-B cells and measure the relative gene expression with microarray analysis.
Materials And Methods

Cell lines and transient transfection
The HEC-1-B cells were purchased from the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in modified Eagle's medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA). And cell lines were maintained at 37 °C in a humidified atmosphere of 5% CO 2 .
The CYPB-siRNA and negative control siRNA (NC-siRNA) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA; sc-35145 and sc-36869, respectively). Cells were 
Cell Proliferation And Clone Formation
Cell proliferation was determined using the Cell Counting Kit-8 assay (CCK-8; Beyotime Biotechnology, Shanghai, China) per the manufacturer's instructions. Cells in the logarithmic growth phase (1 × 10 4 cells/mL per well) were grown in 96-well plates in medium containing 10% FBS in an incubator with 5% CO 2 at 37 °C for 72 h. Afterwards, 5 10 mL of CCK-8 solution was added to each well, and the plates were incubated for an additional 4 h. The absorbance in each well was measured at a wavelength of 450 nm with a microplate reader.
For clone formation, HEC-1-B cells were transfected with CYPB-siRNA for 48 h and were collected and seeded in triplicate into 6-well plates at a density of 1,000 cells/mL per well.
The cells were incubated for 10 days at 37 °C in a 5% CO 2 atmosphere. They were then fixed with 4% paraformaldehyde for 30 min and stained with Giemsa (Beyotime Biotechnology) for 20 min. After washing with double-distilled H 2 O several times, images of the cell plates were taken (Canon, Inc., Tokyo, Japan).
RNA extraction, reverse transcription, qRT-PCR and microarray analysis
Total RNA was extracted using TRIzol, and cDNA was synthesized with PrimeScript RT reagent Kit (TaKaRa, Dalian, China). Gene expression was assessed by qRT-PCR using SYBR Premix Dimer Eraser (Perfect Real Time, TaKaRa) assay kits. Relative fold changes in expression were calculated using the comparative Ct (2 − ∆∆Ct ) method. Purified RNA samples were submitted to Phalanx Biotech (Hsinchu, Taiwan) for microarray analysis. We used the Phalanx Human OneArray Plus Gene Expression Profiling platform 6.1 to analyze the CYPB-mediated alterations of mRNA expression.
Immunohistochemistry (ihc)
Sections (4 µm) were cut from the constructed TMA blocks, deparaffinized, and rehydrated. Heat-induced epitope retrieval was performed onboard of the Leica Bond RX platform at 100 ℃ using EDTA buffer (pH 9.0, Leica) for 20 minutes, followed by 15 min of incubation with anti-CYPB antibody (#43603, Cell Signaling Technology, Danvers, MA, USA) or anti-β-catenin antibody (#8480, Cell Signaling Technology) at room temperature and with Bond™ Polymer Refine Detection kit (Leica Biosystems, Buffalo Grove, IL, USA) 6 for 8 min. The reaction was visualized using 3,3′-diaminobenzidine tetrahydrochloride for 10 min and with hematoxylin as a counterstain. Scoring was performed by pathologists (MK, PR) using Nikon Eclipse microscope on TMA glass slides at 20 × magnification.
Tissues were scored for CYPB expression, and the scoring system reflected the extent and intensity of staining: the intensity was assigned a score of 0, 1, 2, or 3, representing negative, weak, moderate, or strong expression, respectively; while the extent was assigned a score of 0, 1, 2, 3 or 4, representing < 5%, 6-25%, 26-50%, 51-75% and > 75% of cells stained. The overall quantitation of the score was obtained by multiplying the average intensity and score of five different high-power fields (at 400 × magnification).
The samples were divided into two groups based on final staining scores, which ranged from 0 to 7: the high expression group (scores of ≥ 4) and the low expression group (scores of < 4) [23] .
Gene Ontology Functional And Pathway Enrichment Analysis
GO and KEGG pathway enrichment analysis were used for differentially expressed genes (DEGs) using the DAVID database. FDR values of < 0.05 were set as the cut-off criterion for the two analyses.
Statistical analysis
Statistical analysis was performed using SPSS software, version 18.0 (SPSS, Chicago, IL, USA). The chi-square test was used to determine the differences in age and tumor grades between high and low expressed CYPB groups. Differences between two groups were analyzed using Student's t-test for comparison of two groups or by one-way analysis of variance for comparison of more than two groups. P values of < 0.05 were considered statistically significant.
Results
7
CYPB is over expressed in endometrial cancer Seventy-four control tissue samples, consisting of 24 normal endometrium tissue and 50 of atypical hyperplasic endometria, and 96 endometrial cancer tissues were used to validate protein expression by immunohistochemistry. CYPB expression was significantly higher in endometrial cancer tissues compared with non-cancer tissues, and it was higher in intrauterine dysplasia than in the normal endometrium ( Fig. 1 ), suggesting that higher expression of CYPB is associated with the incidence of endometrial cancer. Furthermore, no significant association was observed between CYPB expression and patient age or tumor grades (Table 1) . Table 1 The CypB expression between age and tumor grades. 
CypB expression levels
Downregulation of CYPB inhibits HEC-1-B cell proliferation and colony formation
In order to investigate the role of CYPB in endometrial cancer, we treated the HEC-1-B cell line with CYPB-siRNA. CYPB-siRNA significantly reduced CYPB mRNA expression by over 70% (Figure 2 ), indicating that a highly efficient knockdown of CYPB expression was achieved.
Microscopic observation of the HEC-1-B cells were transfected with CYPB-siRNA or NC-siRNA showed a decrease in cell proliferation after downregulation of CYPB (Figure 3a) .
The results of the CCK-8 assay indicated that, compared control cells, the proliferation of 8 CYPB-knockdown HEC-1-B cells decreased 72h after transfection (Figure 3b ). Finally, CYPB silencing in HEC-1-B cells substantially reduced colony formation as well (Figure 3c ).
Identification of DEGs in endometrial cancer cell with downregulated CYPB expression
We performed a microarray analysis, comparing the global mRNA expression profile between the normal and CYPB-knockdown HEC-1-B cells. A volcano plot of the identified quality-controlled genes (p < 0.05; fold change, > 1) is presented in Figure 4a . The microarray identified 1536 differentially expressed mRNAs in total, of which 652 were upregulated and 884 downregulated in the CYPB-knockdown group. A heat map was generated to show genes that were previously identified as significantly upregulated in HEC-1-B cells (Figure 4b ).
GO functional and pathway enrichment analysis GO and pathway enrichment analysis showed that the DEGs were significantly enriched in cell cycle, glycosphingolipid biosynthesis, adherens junctions, and metabolism pathways.
Important genes and pathways involved in this process are shown in Figure 5 .
Validation of differentially expressed RNA by qRT-PCR
To evaluate the reliability of microarray data, we verified the expression of five differentially expressed mRNA in HEC-1-B cells by qRT-PCR assay. As shown in Figure 6 , the mRNA expression of SREBF1, SPP1, PPIB and PLAT were significantly downregulation in the CypB-knockdown cells. While the CDKN1A mRNA shown a much higher expression in the CypB-knockdown cells. All these results were consistent with the microarray data.
Discussion
Endometrial carcinoma remains one of the leading causes of death among women, and, therefore, the discovery of novel molecular targets for its diagnosis, prognosis, and 9 treatment is required for improving the clinical strategy and outcome for this disease.
Cyclophilins have been implicated in a variety of cancers; however, their expression has not been studied in endometrial carcinoma. There are 16 types of human cyclophilins, cyclophilins A (CYPA) and CYPB being the two most abundant and the most studied ones.
Recent studies have found that CYPA expression is implicated in several cancers, including lung cancer [24, 25] , pancreatic cancer [26, 27] , hepatocellular cancer [28] , and buccal squamous cell carcinoma [29] , and that it might play a role in apoptosis through the activation of caspases and apoptosis-inducing factor. A study with a two-dimensional gel electrophoresis and MALDI-Q-TOF MS/MS-based proteomics approach found that overexpression of CYPA is significantly correlated with a low degree of cancer differentiation, and its overexpression was associated with decreased survival in endometrial carcinoma [30] .
On the other hand, the structurally similar CYPB, which is s is found in the endoplasmic reticulum, has been implicated in STAT3 activation and in the generation of reactive oxygen species in cancer cells [21] . CYPB facilitates the transcriptional activity of STAT5 by inducing the release of the repressor PIAS3, resulting in significantly enhanced STAT5mediated gene expression [11, 15] . At the cell surface, CYPB also serves as a ligand for the CD147 receptor [31] , which regulates MAPK activation, motility, calcium transport [31] [32] [33] , and the expression of the pro-apoptotic protein BIM [34] . Gene expression studies revealed that CYPB is highly upregulated in malignancies. Ablation of CYPB expression in glioblastoma multiforme cells suppresses several canonical oncogenic signaling pathways, including mutant P53, MYC, and CHK1.
Conclusions
In this study, we demonstrated that patients with endometrial cancer exhibit a significantly higher expression of CYPB, suggesting that CYPB expression can be considered an effective indicator for the clinical outcome of endometrial cancer.
Furthermore, our results demonstrate that CYPB acts as an oncogene in endometrial cancer and that silencing its expression affects the expression of many genes involved in the cell cycle, glycosphingolipid biosynthesis, adherens junctions, and metabolism pathways. The expression of real-time qPCR was in accordance with microarray data
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